OSI starts Tarceva Phase III in lung cancer

OSIP began Phase III testing of its Tarceva ( OSI-774) small molecule EGFR inhibitor in combination with carboplatin and paclitaxel to treat non-small cell lung cancer. The 1,000-patient study will be...